Table 2.
Baseline pharmacological treatment in the whole study population and in the two groups separately.
| Drugs | ALL (n = 1728) |
HT (n = 1204) |
HT + COPD (n = 524) |
P |
|---|---|---|---|---|
| ACE-i/ARBs, n (%) | 699 (77) | 497 (77) | 202 (77) | 0.313 |
| CCBs, n (%) | 285 (31) | 199 (31) | 86 (32) | 0.991 |
| β-blockers, n (%) | 227 (25) | 174 (27) | 53 (20) | 0.018 |
| α-blockers, n (%) | 37 (4) | 27 (4) | 10 (4) | 0.795 |
| Diuretics, n (%) | 377 (41) | 265 (41) | 112 (43) | 0.817 |
| Associations, n (%) | 517 (57) | 370 (57) | 147 (56) | 0.289 |
| BP target | 1178 (68) | 825 (68) | 353 (67) | 0.676 |
| Aspirin, n (%) | 380 (22) | 269 (22) | 121 (23) | 0.780 |
| LAMA, n (%) | 285 (54) | |||
| LABA, n (%) | 160 (30) | |||
| LAMA/LABA, n (%)) | 79 (15) |
ACE-i: angiotensin converting enzyme inhibitors; ARBs: angiotensin receptor inhibitors; BP: blood pressure; CCBs: calcium channel blockers; LABA: long-acting β2-agonists; LAMA: long-acting muscarinic antagonists.